# A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

> **NCT01832259** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 30 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Pazopanib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01832259
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2017-02-07
- **Final completion:** 2018-08-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832259, "A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01832259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*